Colorectal cancer (CRC) has shifted from a disease historically associated with aging to a pressing public health crisis affecting the young. Now the second leading cause of cancer-related death in the United States and the primary cause of cancer mortality among adults under 50, its rise has prompted a desperate search for new therapeutic avenues. While the oncology field has seen a revolution in immunotherapy—treatments that harness the body’s own defenses to eradicate malignant cells—these breakthroughs have largely bypassed the vast majority of CRC patients.
Dr. Karin Pelka, an investigator at the Gladstone Institutes and recipient of the prestigious Cancer Research Institute (CRI) Technology Impact Award, is at the vanguard of a movement to bridge this gap. Her research team is moving beyond traditional genetic analysis, choosing instead to "listen in" on the complex molecular conversations occurring within the tumor microenvironment. By decoding these signals, Pelka hopes to transform colorectal cancer from an immunotherapy-resistant diagnosis into a manageable, and perhaps curable, condition.
The Landscape of the Crisis: A Changing Demographic
The narrative of colorectal cancer is evolving. For decades, the medical community viewed CRC as a disease of the elderly, leading to screening protocols that focused on the 50-plus demographic. However, the epidemiology has shifted dramatically. With rising rates of early-onset CRC, clinicians are encountering patients in their 20s, 30s, and 40s who face unique psychological and physiological challenges.
Chronology of Progress and Stagnation
- The Early Era: For decades, the standard of care remained rooted in surgery, chemotherapy, and radiation. These treatments are often physically grueling and carry long-term side effects.
- The Immunotherapy Breakthrough: The advent of immune checkpoint inhibitors marked a paradigm shift in oncology. These drugs effectively "release the brakes" on the immune system, allowing T cells to identify and destroy cancer cells.
- The "dMMR" Success Story: In 2022, a landmark clinical trial provided a glimpse of the future. Researchers discovered that a small subset of patients (roughly 5–10%) with DNA mismatch repair deficiency (dMMR) exhibited an extraordinary response to immunotherapy. In this study, locally advanced rectal cancer patients who received checkpoint inhibitors showed a 100% response rate, with no detectable cancer remaining.
- The Current Impasse: Despite the triumph of the dMMR trial, approximately 90% of CRC patients remain ineligible for this type of immunotherapy. Their tumors, characterized by a different genetic profile, remain "invisible" or resistant to the immune system.
Why Most Cancers Hide: The Immunological Barrier
Immunotherapy relies on a tumor’s visibility. In cancers like melanoma or non-small cell lung cancer, the accumulation of high mutational burdens makes the tumor look "foreign" to the immune system. When the body identifies a foreign threat, it recruits killer T cells to the site. Checkpoint inhibitors act as a magnifying glass, intensifying this natural defense mechanism.
Colorectal cancer, however, is often a "cold" tumor. It does not consistently present the mutations required to alert the immune system. Dr. Pelka notes the frustration of this reality: "The vast majority of colon cancer falls into this relatively large area of tumors where we haven’t quite figured out yet how to use the immune system to fight them."
This is not merely a failure of drug delivery; it is a failure of biological communication. Inside the tumor, there is a dense, chaotic ecosystem of cancer cells, stromal cells, and immune cells. For immunotherapy to work, these components must coordinate a response. Currently, for the 90% of CRC patients, that coordination never occurs.
Mapping the "Immune Hubs"
Dr. Pelka’s research at the Gladstone Institutes has identified a critical, previously overlooked feature of the tumor environment: "immune hubs." These are structured clusters within the tumor where killer T cells, cancer cells, and structural tissue engage in intense molecular signaling.
The Pelka Lab’s findings suggest that these hubs act as the command centers of the tumor microenvironment. Depending on the "dynamics of the communication cascade" within these hubs, the result can either be the destruction of the tumor or the promotion of its growth.
The Significance of the Hubs
Data from the Pelka Lab indicates that the presence of these immune hubs—in a specific activated state—is a highly predictive biomarker for immunotherapy response. Crucially, this is not a phenomenon unique to colorectal cancer; these hubs appear to be conserved across diverse tumor types, including lung cancer and melanoma.
If these hubs are the engines of the immune response, the question shifts from "How do we kill the cancer?" to "How do we activate these hubs?" Dr. Pelka’s team is now working to determine what prevents these hubs from forming—or remaining active—in the patients who currently fail to respond to standard immunotherapy.
The AI Revolution: Decoding the "Language" of Cells
To solve a problem of this magnitude, the human brain requires assistance. Dr. Pelka is leveraging a CRI Technology Impact Award to deploy "Geneformer," a foundational artificial intelligence model developed in collaboration with Dr. Christina Theodoris.
Geneformer is essentially a large language model for biology. Just as ChatGPT learns the patterns of human syntax to predict the next word in a sentence, Geneformer has been trained on tens of millions of human cell profiles to learn the "syntax" of gene activity.
How AI Accelerates Discovery:
- Identifying Master Regulators: The AI sifts through massive datasets to identify the "master molecular switches" that dictate whether a cancer cell is visible to the immune system.
- Spatial Transcriptomics: The team is mapping these molecular interactions across the physical landscape of the tumor, creating a 3D map of the battleground between the immune system and the cancer.
- Cross-Patient Application: By identifying universal molecular switches, the goal is to develop therapies that work for a wide range of patients, moving away from the "one-size-fits-all" genetic screening that currently limits treatment options.
"The CRI Technology Impact Award is a perfect example of bringing together new technologies with the problem of getting cancer immunotherapy to work," Dr. Pelka says. "Having a foundation willing to take a bet early on—when the science is not yet ready to be employed widely, but where early discoveries can really move the needle—that is often research that is hard to fund, because it is very risky."
Implications: The Urgent Need for a Living Therapeutic
For a young adult diagnosed with colorectal cancer, the passage of time is the most precious commodity. Traditional targeted therapies offer precision, but they suffer from a fatal flaw: evolution. Cancer cells are masters of adaptation, often developing resistance to targeted drugs within months or years.
Immunotherapy, by contrast, is a "living therapeutic." It is capable of evolving alongside the cancer. When it works, it creates a durable, long-term surveillance system that keeps the disease in check, potentially preventing the recurrences that define the current CRC patient experience.
Prevention: A Note on Public Health
While researchers like Dr. Pelka race to find cures for existing cancers, the medical community emphasizes that the most effective tool in the arsenal remains early detection. Colorectal cancer is unique in that it is often preventable through routine screening. A colonoscopy can identify and remove precancerous polyps years before they become malignant. For the general population, starting regular screenings at age 45 remains the most powerful step an individual can take to avoid the path of a CRC diagnosis entirely.
The Path Forward
The work being conducted at the Gladstone Institutes represents a shift in oncology from descriptive science to predictive, actionable intelligence. By treating the tumor not as a static mass but as a dynamic, communicative system, Dr. Pelka is providing a roadmap to turn the tide on the second leading cause of cancer death.
If the "immune hubs" can be successfully manipulated, and if the AI-identified "master switches" can be flipped, the next decade could see the 90% of currently ineligible patients finally gaining access to the curative potential of immunotherapy. For the patients currently planning their futures, that isn’t just research—it is the hope of a life reclaimed.
